The ‘Indian strain’ of the coronavirus carries higher transmissibility similar to the UK variant, but there is little evidence so far of it being more lethal than the original virus, experts have said.
The B.1.617 variant of SARS-CoV2, also being called a ‘double mutant’ or the ‘Indian strain’, has been found prevalent largely in Maharashtra and Delhi that have been severely hit by a devastating second wave of the pandemic.
In many cities in Maharashtra — the worst-hit state in the country — the B.1.617 variant was found in more than 50 per cent of samples on which genome sequencing was conducted, while the proportion of the UK variant was 28 per cent in the second week of March, Sujeet Singh, the Director of the National Centre for Disease Control, had said in a webinar on genome sequencing last week.
The number of coronavirus cases has exploded in Delhi and Maharashtra over the last few weeks and crippled the healthcare sector. Several hospitals in Delhi have reported an acute shortage of medical oxygen and are scrambling to save the lives of patients.
Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology (IGIB), told PTI, “As far as we know, neither the UK variant nor this one (B.1.617) is associated with increased severity of illness or death. The UK strain is proven to have higher transmissibility and B.1.617 may have increased transmissibility.”
IGIB is one of the 10 laboratories spread across the country that are involved in genome sequencing of the virus.
He, however, added that there is no comparison of which variant has increased transmissibility.
“But looking at Maharashtra’s experience, it looks more transmissible, but it is yet to be proven. Looking at the general evidence, it (B.1.617) may be more transmissible,” he said.
When asked about the increased deaths in the state in comparison to the first wave last year, Agrawal said this has in direct relation with how transmissible the variant is. The more the patients are infected, the more will be the toll, he said.
The B.1.617 variant has three new spike protein mutations. Two mutations — E484Q and L452R — are in the area important for antibody-based neutralisation.
The third mutation — P681R — allows the virus to enter cells a little better. These are defining characteristics of the variant.
Soumitra Das, the Director of the National Centre for Biological Sciences, said there is no report on the lethality of B.1.617 yet.
NCBS in Kalyani in West Bengal is one of the 10 organisations involved in the genome sequencing of the coronavirus.
In a webinar on genome sequencing of the coronavirus last week, Das had said variants found in India are not really escaping our vaccinated sera, suggesting that the available vaccines are effective on them.
In its initial result on the efficacy of the Covishield vaccine, the Centre for Cellular and Molecular Biology, another premier institute that has been studying the virus, said the vaccine is effective against the B.1.617 strain.